Representative’s Warrant. On the Closing date, the Company shall have delivered to the Representative an executed copy of the Representative’s Warrant.
Representative’s Warrant. The Company hereby agrees to issue to the Representative (and/or its designees) on the Closing Date warrants for the subscribe for of an aggregate number of Ordinary Shares equal to 5% of the number of Ordinary Shares issued in the Offering, pursuant to a warrant agreement in the form attached hereto as Exhibit A (the “Representative’s Warrants”), at an initial exercise price of $[●], which is equal to 120% of the public offering price for one Ordinary Share. The Representative’s Warrant and the Ordinary Shares issuable upon exercise of the Representative’s Warrants are hereinafter referred to together as the “Representative’s Securities.” The Representative understand and agree that there are significant restrictions pursuant to FINRA Rule 5110 against transferring the Representative’s Warrants and the underlying securities during the one hundred eighty (180) days after the Effective Date and by its acceptance thereof shall agree that it will not sell, transfer, assign, pledge or hypothecate the Representative’s Warrants, or any portion thereof, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities for a period of one hundred eighty (180) days following the Effective Date to anyone other than (i) an Underwriter or a selected dealer in connection with the Offering, or (ii) a bona fide officer or partner of the Representative or of any such Underwriter or selected dealer; or as otherwise expressly permitted by Rule 5110(g), and only if any such transferee agrees to the foregoing lock-up restrictions.
Representative’s Warrant. The Company hereby agrees to issue to the Representative (and/or its designees) on the Closing Date a warrant for the purchase of up to 115,000 shares of common stock equal to 5% of the total number of shares of common stock sold in this offering, including any shares issued upon exercise of the underwriters’ over-allotment option, pursuant to a warrant agreement in the form attached hereto as Exhibit B (the “Representative’s Warrant”). The Representative’s Warrants will be exercisable during the five-year period from the commencement of sales of this Offering at a per share exercise price of $[] (125.0% of the public offering price of the common stock) and may be exercised on a cashless basis. The Representative’s Warrant and the shares of Common Stock issuable upon exercise of the Representative’s Warrant are hereinafter referred to together as the “Warrant Shares.” The Representative understands and agrees that there are significant restrictions pursuant to FINRA Rule 5110(e) against transferring the Representative’s Warrant and the underlying securities during the 180 days after the commencement date of sales in the Offering and by its acceptance thereof shall agree that it will not sell, transfer, assign, pledge or hypothecate the Representative’s Warrant, or any portion thereof, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities for a period of 180 days after the commencement date of sales in the Offering, except as expressly permitted by FINRA Rule 5110(e), and only if any such transferee agrees to the foregoing lock-up restrictions. The Representative and its affiliates or employees will also be entitled to one demand registration of the sale of the shares underlying the Representative’s Warrants and unlimited “piggyback” registration rights. Upon written demand of the holders of at least 51% of the Representative’s Warrants, the Company agrees to register, on one occasion, all or any portion of the Warrant Shares. On such occasion, the Company shall file a registration statement with the Commission covering the Warrant Shares within 60 days after receipt of such demand notice, and shall use its reasonable best efforts to have the registration statement declared effective promptly thereafter, subject to compliance with review by the Commission. The Company shall bear all fees and expenses associated with the registration of the Warrant Shares, ...
Representative’s Warrant. The Representative shall have received the Representative’s Warrant referenced in Section 4(p) with the respect to the Securities to be delivered on such Closing Date.
Representative’s Warrant. On each Closing Date, the Company shall sell to the Representative, for an aggregate purchase price of $50, a warrant in the form attached as Exhibit B hereto (the “Representative’s Warrant”) to purchase the number of shares of the Company’s Common Stock equal to 5.0% of the Firm Shares issued on such Closing Date (rounded up to the nearest whole share) at an exercise price equal to 110% of the public offering price per share in the Offering.
Representative’s Warrant. On the First Closing Date, the Company shall issue and sell to you, for a total purchase price of $5.00, and upon the terms and conditions set forth in the form of Representative's Warrant filed as an exhibit to the Registration Statement, a warrant entitling you to purchase 80,000 Units and 15,000 Class B Shares (the "Representative's Warrant"). In the event of conflict in the terms of this Agreement and the Representative's Warrant, the terms and conditions of the Representative's Warrant shall control.
Representative’s Warrant. The Company hereby agrees to issue to the Representative (and/or its designees) on the First Closing Date (as defined below) warrants to purchase such number of Ordinary Shares equal to ten percent (10%) of the sum of (i) the Firm Shares, plus (ii) if any, the Option Shares issued at the Closing (the “Representative’s Warrant”). The Representative’s Warrant may be purchased in cash or via cashless exercise, shall be exercisable for a period of five years from the Effective Date (as defined below) of the Registration Statement (as defined below) and will terminate on the fifth anniversary of the Effective Date of the Registration Statement. The exercise price of the Representative’s Warrant is equal to one hundred and ten percent (110%) of the initial public offering price of a Firm Share. The Representative’s Warrant and the Ordinary Shares issuable upon exercise of the Representative’s Warrant will be deemed compensation by FINRA, and therefore will be subject to FINRA Rule 5110. In accordance with FINRA Rule 5110(e)(1), neither the Representative’s Warrant nor any of the Ordinary Shares issued upon exercise of the Representative’s Warrant may be sold, transferred, assigned, pledged or hypothecated, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities by any person, for a period of 180 days beginning on the date of commencement of sales of this Offering pursuant to which the Representative’s Warrant is being issued, subject to certain exceptions permitted by FINRA Rule 5110(e)(2).
Representative’s Warrant. The Company hereby agrees to issue to the Representative (and/or its designees) on the applicable Closing Date and/or Option Closing Date, as the case may be, Warrants to purchase such number of Shares equal to ten percent (10%) of the Shares issued at the Closing (for the avoidance of doubt, including the Additional Shares) (the “Representative’s Warrant”). The Representative’s Warrant shall be exercisable, in whole or in part, commencing 180 days from the Effective Date and expiring on the three (3) year six (6) month anniversary of the Effective Date at an initial exercise price of $[●] per Share, which is equal to one hundred twenty-five percent (125%) of the initial public offering price of a Firm Share. The Representative’s Warrant and the Shares issuable upon exercise of the Representative’s Warrant are hereinafter referred to collectively as the “Representative’s Securities.” The Firm Shares, the Option Shares and the Representative’s Securities are hereinafter referred to collectively as the “Securities.”
Representative’s Warrant. At each Closing Date, as applicable, the Company shall issue the Representative’s Warrant to the Representative, as set forth in Section 1(d) hereof.
Representative’s Warrant. The Company hereby agrees to issue to the Representative (and/or its respective designees) on the Closing Date, Warrants to purchase up to an aggregate of ______ shares of Common Stock [7% OF THE NUMBER OF SHARES SOLD IN THE OFFERING] (the “Representative’s Warrants”). The Representative’s Warrants shall be exercisable, in whole or in part, commencing 180 days from the Effective Date and expiring on the three-year anniversary of the Effective Date at an initial exercise price of $____ per share of Common Stock, which is equal to one hundred and twenty five percent (125%) of the initial public offering price of a Unit. The Representative’s Warrants and the shares of Common Stock issuable upon exercise of the Representative’s Warrants are hereinafter referred to collectively as the “Representative’s Securities.”
